Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a Randomized Phase IIb Study of Abatacept in Psoriatic Arthritis

In this study abatacept 30/10 mg/kg and 10 mg/kg doses were associated with greater improvements from baseline in MRI detected synovitis and tenosynovitis, respectively, compared with placebo, confirming the clinical outcomes. Indeed, inflammatory components demonstrated the greatest change from baseline.

This study sought to determine whether the novel scoring system OMERACT PsAMRIS shows sensitivity to change with an agent known to impact clinical outcomes in PsA. The results encourage further use of PsAMRIS scoring in observational cohorts and clinical trials for objective assessment of the influence of new drugs on joint inflammation and damage progression in PsA.